| Filed On | Filing |
|---|---|
| 10 Nov 2026 | S-8 |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027 |
| 21 Oct 2026 | 144 |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 10 Sep 2026 |
Form 4: Cohlhepp Ryan, Director
Received 17,500 shares by exercise or conversion ($66.3K) · Sold 17,500 shares ($401K) |
| 08 Sep 2026 | 144 |
| 08 Sep 2026 | 144 |
| 25 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
This SUB-SUBLEASE AGREEMENT (this “Sub-Sublease”) is made as of August 21, 2026 (the “Effective Date”), by and between WAYFAIR LLC, a Delaware limited liability company having an office at 4 Copley Place, Boston, Massachusetts 02116 (“Su... |
| 14 Aug 2026 |
Form 4: Larson Jennifer, Chief Financial Officer
Granted 285,000 Stock Option (Right to Buy) |
| 14 Aug 2026 |
Form 3: Larson Jennifer, Chief Financial Officer
No securities owned |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 |
Form 4: Hyep Ivan, Chief Financial Officer
Received 12,500 shares by exercise or conversion ($47.4K) · Sold 12,500 shares ($350K) |
| 12 Aug 2026 |
Form 4: Mazumdar Claire, Director
Received 10,000 shares by exercise or conversion ($37.9K) · Sold 10,000 shares ($280K) |
| 12 Aug 2026 |
Form 4: Cohlhepp Ryan, Director
Received 18,750 shares by exercise or conversion ($71.1K) · Sold 18,750 shares ($525K) |
| 11 Aug 2026 | S-8 |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth |
| 10 Aug 2026 | 144 |
| 10 Aug 2026 | 144 |
Loading...